CompletedPhase 2NCT02794857
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
- Principal Investigator
- Gil Block, MD, PhDNeuraltus Pharmaceuticals, Inc.
- Intervention
- NP001(drug)
- Enrollment
- 138 enrolled
- Eligibility
- 21-80 years · All sexes
- Timeline
- 2016 – 2017
Study locations (22)
- St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States
- Mayo Clinic Arizona, Scottsdale, Arizona, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Irvine, Department of Neurology, Orange, California, United States
- Forbes Norris MDA/ALS Research Center, CPMC, San Francisco, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Emory University, Department of Neurology, Atlanta, Georgia, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Clinical & Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- Carolinas Medical Center, Neurosciences Instutite-Neurology, Charlotte, North Carolina, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02794857 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)